Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FT500

Cell therapy (NK cells) · Kills target cells · developed by Fate Therapeutics

Phase 1 Most advanced trial (none active)
FATE Developer
1 Registered trials

What is FT500?

FT500 is an off-the-shelf natural killer cell preparation derived from a clonal induced pluripotent stem cell line. It binds stress-induced ligands on tumor cells, leading to tumor cell lysis, and secretes inflammatory cytokines and chemokines. It is being studied in advanced solid tumors, lymphoma, and several cancers including gastric, colorectal, head and neck, lung, breast, and renal cell carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (NK cells)
Mechanism
Kills target cells
Pathways
interferon-gamma and TNF-alpha cytokine secretion, chemokine signaling (CCL3, CCL4, CCL22, CXCL10), T-cell recruitment and activity
Therapy area
Oncology
Developer
Fate Therapeutics (FATE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03841110 Phase 1 Advanced Solid Tumors Completed FATE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid TumorsColorectal CancerEGFR Positive Solid TumorGastric CancerHead and Neck CancerHepatocellular CarcinomaHER2-positive Breast CancerLymphomaMelanomaNSCLCPancreas CancerRenal Cell CarcinomaSmall Cell Lung CancerSquamous Cell Carcinoma

More from Fate Therapeutics

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the FATE page.

Follow FATE, the company behind FT500

See FATE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

FATE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.